Our journey to success built on synergies and joining forces
Hermes Medical Solutions has been able to forge strong alliances, built on trust, expertise and experience. These partnerships are allowing Hermes Medical Solutions and their counterparts to reach new goals in collaboration.
The Artificial Intelligence in Medicine (AIM) program is a research program of the Department of Medicine at Cedars-Sinai Medical Center. The AIM program seeks to develop software to allow computers to process and analyze three-dimensional images of the heart in much the same way an experienced human operator would.
The Company’s mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective through the provision of radiopharmaceutical products, Technegas (for lung imaging) and Molecular Imaging / Positron Emission Tomography radiopharmaceuticals (used in cancer, brain and cardiac imaging). Our customers are nuclear medicine departments located within hospitals and clinics.
Developed in conjunction with the University of Michigan, INVIA is dedicated to advancing patient care by developing state-of-the-art, quantitative review and reporting software solutions for cardiac imaging. With a foundation of clinically validated algorithms, 4DM provides advanced cardiovascular quantification and image displays in a single, configurable application which has been commercially available for more than 20 years.
Isologic Innovative Radiopharmaceuticals is a nationwide radiopharmaceutical company, dedicated to nuclear medicine and the science of Radiopharmaceutical production. We have over 170 colleagues with significant experience, expertise and networks in Nuclear Pharmacy to provide our customers and patients with reliable; safe and high quality radiopharmaceutical products and services.
Find, Fight and Follow. Progenics Pharmaceuticals, Inc. develops innovative medicines and other technologies to identify, target and treat cancer. Our pipeline includes: (1) therapeutic agents designed to precisely target cancer (AZEDRA® and 1095); (2) PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM); and (3) imaging analysis tools.